GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Hepion Pharmaceuticals (Hepion Pharmaceuticals) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Hepion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Hepion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Hepion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hepion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.


Hepion Pharmaceuticals  (NAS:HEPA) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Hepion Pharmaceuticals EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)
Comparable Companies
ACER VINC HARP ELEV SKYE ICU CBIO PLUR UNCY ONCT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Website
https://www.hepionpharma.com
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Executives
Peter Wijngaard director 8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster officer: Chief Scientific Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi director 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan officer: Chief Financial Officer C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: CEO and President
Donald E Garlikov 10 percent owner 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson director
Thomas Phd Adams director
Gabriel Cerrone 10 percent owner VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai officer: Chief Medical Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein director, officer: Chief Executive Officer 1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa director C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung officer: Chief Financial Officer C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170